# Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

> **NCT00669903** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 100 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AZD0328
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00669903
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to stop further development of AZD0328
- **Last updated:** 2010-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669903, "Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00669903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*